

FILING BY "EXPRESS MAIL" UNDER 37 CFR 1.10

EL 913014820US
Express Mail Label Number

November 16, 2001
Date of Deposit

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF

ZIMMERMANN ET AL.

APPLICATION NO: Not Yet Known

FILED: Herewith

Continuation of Serial No.: 09/463,097

Filed: January 18, 2000

FOR: CRYSTAL MODIFICATION OF A N-PHENYL-2-PYRIMIDINEAMINE
DERIVATIVE, PROCESSES FOR ITS MANUFACTURE AND ITS
USE

Assistant Commissioner for Patents
Washington, D.C. 20231

PRELIMINARY AMENDMENT

Sir:

Prior to calculation of the filing fee, please enter the following amendment:

IN THE SPECIFICATION

On page 1, before the first paragraph, please insert the following:

--This is a continuation application of pending U.S. application Serial No.
09/463,097 filed January 18, 2000--.


IN THE CLAIMS

Delete Claims 1-12.

Please add the following claims:


13. A method of preventing or treating restenosis comprising administering a
therapeutically effective amount of a crystalline form of the monomethanesulfonic acid

addition salt of a compound of formula I,



which is non-hygroscopic in a glass climatic chamber at 25 °C and relative humidities up to and including 93%, to a patient in need thereof.

14. A method of inhibiting or reducing cellular proliferation and migration comprising administering a therapeutically effective amount of the compound of formula I



which is non-hygroscopic in a glass climatic chamber at 25 °C and relative humidities up to and including 93%, to a patient in need thereof.

15. The method of claim 14 wherein the cells are smooth muscle cells.

STATUS OF THE CLAIMS

Claims 1-12 were present in the application.

Claims 1-12 have been deleted.

Claims 13-15 have been added and are presented for consideration.

REMARKS

This Preliminary Amendment is presented to add claims directed to methods of treatment. Support for the claims can be found on pages 12 through 16 of the specification.

In view of the foregoing, Applicants submit that the Application is now in condition for allowance and respectfully requests early notice to that effect.

Respectfully submitted,

Novartis Corporation
Patent and Trademark Dept.
564 Morris Avenue
Summit, NJ 07901-1027
(908) 522-6923



Gregory D. Ferraro
Attorney for Applicants
Reg. No. 36,134

Date: November 16, 2001